

Lupron Depot[®] (leuprolide acetate for depot suspension), leuprolide acetate Medication Precertification Request

Page 1 of 2

Aetna Precertification Notification Phone: 1-866-752-7021 (TTY: 711)

FAX: 1-888-267-3277

For Medicare Advantage Part B: Please Use Medicare Request Form

	(All fields must be o	completed and legible for	r pre	ecertification revie	ew.)				
lease indicate: Start o	f treatment: Start date	1 1							
	uation of therapy, Date of		1	1					
recertification Requested	• •		•	Phone:			Fax:		
A. PATIENT INFORMATION									
irst Name:		Last Name:					DOB:		
Address:		1	Cit				State:	ZIP:	
								IZIP.	
Home Phone:	Work Phone:			II Phone:			Email:	_	
Patient Current Weight:		nt Height: inche	s o	rcms	Allergie	s:			
B. INSURANCE INFORMATI	ON								
Aetna Member ID #:	Does patient have other coverage? ☐ Yes ☐ No								
Group #:		If yes, provide ID#:			Carrier	Name:			
nsured:		Insured:							
Medicare: Yes No If		Me	edic	aid: 🗌 Yes 🗌] No If	yes, provid	de ID #:		
C. PRESCRIBER INFORMA	TION								
First Name:		Last Name:			(Check One	e):	D.O.	
Address:			(City:			State:	ZIP:	
Phone:	Fax:	St Lic #:	1	NPI #:]	DEA #:		UPIN:	
Provider Email:		Office Contact Name:					Phone:	-	
Specialty (Check one): En	docrinologist	cologist 🗆 Oncolog	ist	☐ Other			1		
D. DISPENSING PROVIDER									
Place of Administration:	ADMINISTRATION IN C	KMATION		Dispensing Pr	ovider/	Pharmacy	Patient Selec	ted choice	
Self-administered	☐ Physician's Office			Dispensing Provider/Pharmacy: Patient Selected choice ☐ Physician's Office ☐ Retail Pharmacy					
☐ Outpatient Infusion Center	Phone:						=		
Center Name:						=	="		
☐ Home Infusion Center Phone:			_	Name: Address:					
Agency Name:		-				Fax:			
☐ Administration code(s) (CF Address:		-	Phone: Fax: TIN: PIN:						
E. PRODUCT INFORMATION							1 114		
Request is for: Lupron D		for denot suspension) [leuprolide a	cetate				
Dose:	spot (icapionae acctate			icapionae at	cciaic				
F. DIAGNOSIS INFORMATION	DN - Please indicate prima		-		annlical	ole			
Primary ICD Code:							D Code:		
G. CLINICAL INFORMATION		nation must be complet	ed i	n its entirety for	all pred	ertification	requests.		
☐ Yes ☐ No Is this reques				<u> </u>	ч. р. ос				
	e Lupron Depot-PED form	for this request.							
For Initial Requests (clinical d	•	•							
☐ Breast cancer									
☐ Endometriosis		201.01			Б.	, ,,			
☐ Please indicate how long☐ Epithelial ovarian cancer	the patient has received the	erapy with the requested	d dru	ug and Lupaneta	Раск: _	(mont	ns)		
☐ Fallopian tube cancer									
☐ Gender dysphoria									
Ovarian cancer- malignan	sex cord-stromal tumors	(granulosa cell tumor	s)						
☐ Preservation of ovarian fu	nction								
Primary peritoneal cancer									
Prostate cancer									
└── Yes ☐ No Has the patient had an ineffective response, contraindication, or intolerance to Eligard? ☐ Recurrent menstrual related attacks in acute porphyria									
☐ Recurrent mensural relations and telephone in Recurrent salivary gland t		, riu							
Uterine leiomyomata (fibro									
-> Please indicate how long the patient has received therapy with the requested drug and Lupaneta Pack: (months)									



Lupron Depot[®] (leuprolide acetate for depot suspension), leuprolide acetate Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification

Phone: <u>1-866-752-7021 (TTY: 711)</u>

FAX: <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB		
6. CLINICAL INFORMATION (cont	inued) – Required clinical information musi	t be completed in its <u>entirety</u> for all prec	certification requests.		
or Continuation Requests (clinica	l documentation required for all request	<u>:s):</u>			
	experienced clinical benefit to therapy while experienced an unacceptable toxicity while	3 (3)	stosterone less than 50 ng/dL)?		
I. ACKNOWLEDGEMENT					
Request Completed By <i>(Signatu</i>	re Required):		Date:/ /		
any insurance company by providi	request for authorization of coverage of ing materially false information or conce d subjects such person to criminal and ci	als material information for the purpo			

The plan may request additional information or clarification, if needed, to evaluate requests.